Yuhan Corporation to create a state-of-the-art R&D cluster in Gunpo-City, South Korea

Yuhan Corporation is working together with Gunpo City, South Korea to create a high-tech bio research base and CMC center in the industrial area of Dangjeong-dong, Gunpo. Yuhan Corporation will make an investment of approximately 80 billion Won ($66.7M USD) towards the bio research center and CMC center project. Through the establishment of this bio […]

Yuhan Corporation to invest 1.6 billion Won (1.34 million USD) in Yuhan USA U.S. Open Innovation Investment Continues

Yuhan USA strengthens its role as a ‘venture capital’. They purchased 750,000 shares of Processa Pharmaceuticals this year. Yuhan Corporation is spurring overseas open innovation expansion and strengthening its global position by continuously investing in ‘Yuhan USA’, a leading edge for global advancement.  According to industry sources on October 11th, Yuhan Corporation acquired 1.5 million shares by investing 1.667 billion Won (1.4 million […]

Processa Pharmaceuticals’ PCS12852, originally developed by Yuhan Corp, cleared by FDA to Proceed with Ph2a Trial for Gastroparesis

Processa Pharmaceuticals announced that they have been cleared by the FDA to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis. PCS12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist, originally developed by Yuhan Corporation in South Korea, and exclusively licensed to Processa Pharmaceuticals […]

[Job Opening] Associate, Business Operations – San Diego office

Job description Responsibilities: Provide administrative support to include arranging travel plans and meetings; interact and liaise with members of the functional team, management and external clients Perform office duties that include ordering supplies and maintaining an organized filing system of paper and electronic documents File and retrieve corporate records, documents, and reports. Accurately record minutes […]

Yuhan to license out a gastrointestinal drug candidate to Processa for $415 million

Yuhan Corporation entered into a licensing agreement worth up to $415 million with Processa Pharmaceuticals for the development of YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders (FGID). YH12852 is an agonist that exhibits excellent selectivity to a receptor (5-HT4) that plays an essential role in the regulation […]

Yuhan USA’s 2019 Recap

With 2020 just around the corner, let’s take a look back at our 2019!It has been a wonderful year for us here at Yuhan USA and may the next year be full of greater success.